Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Recombinant human angiostatin well tolerated in cancer patients

Oct. 31, 2003

Acceptable safety profile described for oral diflomotecan in solid tumors

Oct. 31, 2003

Targeted therapy of AML with anti-FLT3 antibody under evaluation

Oct. 30, 2003

Canadian approval for Gleevec for newly diagnosed Ph+ CML

Oct. 30, 2003

Sankyo intensifies development of anticancer drugs

Oct. 30, 2003

New inhibitors of ZAP-70, FAK and/or Syk designed at Novartis

Oct. 30, 2003

EN-3247 fails to prevent oral mucositis in pivotal trial

Oct. 29, 2003

Bay-43-9006 enters pivotal phase III trial in kidney cancer

Oct. 29, 2003

Yamanouchi describes new antitumor agents from Pseudomonas species

Oct. 29, 2003

Novel HDAC inhibitors isolated from a marine sponge by Yamanouchi scientists

Oct. 29, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...